Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus immunoglobulin
- Development stage
- Phase 4
- Lead developer
- MedImmune
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Respiratory syncytial virus immunoglobulin is a **human plasma-derived immunoglobulin preparation containing high titers of antibodies against respiratory syncytial virus (RSV)**. It is administered intravenously and was developed for the prevention of severe RSV infection in high-risk infants, particularly those with bronchopulmonary dysplasia, congenital heart disease, or prematurity. The product is primarily composed of IgG with trace amounts of IgA and IgM, and undergoes viral inactivation steps. Its primary mechanism is passive immunization via neutralization of RSV, thereby preventing infection or reducing severity. It is no longer widely marketed due to newer monoclonal antibody products, but evidence supports its effectiveness in decreasing hospitalization and ICU admissions when used as prophylaxis during RSV seasons[1][5].
- Brand names
- RespiGam
- Other names
- respiratory syncytial virus immune globulin intravenousRSV immune globulin intravenousRSV-IGIV
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on respiratory syncytial virus immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus immunoglobulin.